265: Novavax's CEO promises a turnaround & how Lilly roiled the obesity market
The Readout Loud
00:00
Novavax's CEO: John Jacobs
In February, Novavax warned its investors that there is a substantial doubt about its ability to continue operating for the next year. The company's COVID vaccine did receive emergency use authorization, but it's not widely used in the US. John Jacobs joins us now to talk about the path ahead for Novavax.
Transcript
Play full episode
